[go: up one dir, main page]

BR9711225A - Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer - Google Patents

Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer

Info

Publication number
BR9711225A
BR9711225A BR9711225A BR9711225A BR9711225A BR 9711225 A BR9711225 A BR 9711225A BR 9711225 A BR9711225 A BR 9711225A BR 9711225 A BR9711225 A BR 9711225A BR 9711225 A BR9711225 A BR 9711225A
Authority
BR
Brazil
Prior art keywords
propentophylline
alzheimer
transdermal
disease
compositions
Prior art date
Application number
BR9711225A
Other languages
English (en)
Inventor
Srinivasan Venkateshwaran
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of BR9711225A publication Critical patent/BR9711225A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9711225A 1996-08-22 1997-08-22 Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer BR9711225A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/701,711 US5762953A (en) 1996-08-22 1996-08-22 Transdermal propentofylline compositions for the treatment of Alzheimers disease
PCT/US1997/014869 WO1998007400A1 (en) 1996-08-22 1997-08-22 Transdermal propentofylline compositions for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
BR9711225A true BR9711225A (pt) 1999-08-17

Family

ID=24818368

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711225A BR9711225A (pt) 1996-08-22 1997-08-22 Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer

Country Status (12)

Country Link
US (1) US5762953A (pt)
EP (1) EP1028682A1 (pt)
JP (1) JP2000516633A (pt)
KR (1) KR20000065244A (pt)
CN (1) CN1226152A (pt)
AU (1) AU4159897A (pt)
BR (1) BR9711225A (pt)
CA (1) CA2255580A1 (pt)
IL (1) IL127146A0 (pt)
NZ (1) NZ332746A (pt)
WO (1) WO1998007400A1 (pt)
ZA (1) ZA977310B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6352715B1 (en) * 1998-02-19 2002-03-05 Sagittarius Life Science Corp Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease
WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
CA2398641A1 (en) * 2000-01-31 2001-08-02 Panmedix Incorporated Measuring pharmaceutical cognitive impairment
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
JP2003531157A (ja) * 2000-04-26 2003-10-21 ワトソン ファーマシューティカルズ, インコーポレイテッド オキシブチニン治療に関連した有害な経験の最小化
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US7921999B1 (en) 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PL1606261T3 (pl) 2003-03-10 2010-04-30 Astrazeneca Ab Nowy sposób przygotowania roflumilastu
WO2006097456A1 (en) * 2005-03-16 2006-09-21 Nycomed Gmbh Taste masked dosage form containing roflumilast
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
US9254325B2 (en) 2010-10-28 2016-02-09 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbed preparation
JP5813652B2 (ja) * 2010-10-28 2015-11-17 久光製薬株式会社 経皮吸収型製剤
EP2772252B1 (en) * 2011-10-26 2020-03-18 Hisamitsu Pharmaceutical Co., Inc. Oxybutynin-containing transdermal absorption preparation
KR101733085B1 (ko) * 2016-04-20 2017-05-08 전남대학교산학협력단 귀리 추출물 아베난쓰라마이드 c 또는 이의 유도체를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약제학적 조성물 및 건강기능식품

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
JPH062675B2 (ja) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 記憶障害治療剤
GB8621869D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Treatment
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine

Also Published As

Publication number Publication date
CA2255580A1 (en) 1998-02-26
EP1028682A1 (en) 2000-08-23
IL127146A0 (en) 1999-09-22
WO1998007400A1 (en) 1998-02-26
NZ332746A (en) 2000-01-28
US5762953A (en) 1998-06-09
AU4159897A (en) 1998-03-06
ZA977310B (en) 1998-03-27
CN1226152A (zh) 1999-08-18
JP2000516633A (ja) 2000-12-12
KR20000065244A (ko) 2000-11-06

Similar Documents

Publication Publication Date Title
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
BR9408407A (pt) Uso de inibidores pla2 como tratamento para doença de alzheimer
BR9604872A (pt) Composição para tratamento de cabelo
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
FI20000720L (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
PT861081E (pt) Utilizacao de epinastina para o tratamento de dores
FI953915A0 (fi) Dupuytrenin taudin lievittämiseen
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
FR2760189B1 (fr) Composition de traitement capillaire
DE69838785D1 (de) Pharmazeutische mittel zur behandlung von zerebralen amyloidosis
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
NO982562D0 (no) Sammensetning for behandling av smerte
FI952953L (fi) Aineita metabolisten luustosairauksien hoitamiseen
BR9507732A (pt) Composição farmacêutica para o tratamento de glaucoma
EP0981545A4 (en) TREATMENT OF OSTEOPOROSIS
NO970127D0 (no) Topiske sammensetninger for behandling av hudsykdom
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
FR2745719B1 (fr) Composition pour le traitement d'affections cutanees
ID24521A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
ITMI942452A0 (it) Composizione per il trattamento cosmetico delle strutture cheratiniche
UA25492A (uk) Спосіб лікуваhhя хвороби гіршпруhга

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]